Literature DB >> 9352120

Ineffectiveness of the presence of H-ras/p53 combination of mutations in squamous cell carcinoma cells to induce a conversion of a nontumorigenic to a tumorigenic phenotype.

H Lee1, D Li, T Prior, B C Casto, C M Weghorst, C F Shuler, G E Milo.   

Abstract

Human tumor cells have properties in vitro or in surrogate hosts that are distinct from those of normal cells, such as immortality, anchorage independence, and tumor formation in nude mice. However, different cells from individual tumors may exhibit some, but not all of these features. In previous years, human tumor cell lines derived from different tumor and tissue types have been studied to determine those molecular changes that are associated with the in vitro properties listed above and with tumorigenicity in nude mice. In the present study, seven cell lines derived from human tumors were characterized for p53 and ras mutations that may occur in SCC tumor phenotypes and for tumor formation in nude mice. This investigation was designed to examine whether co-occurrence of mutated ras and p53 lead to a malignant stage in the progression process. None of the seven cell lines contained mutations in the recognized "hot spots" of the p53 tumor suppressor gene, but four had a nonsense/splice mutation in codon 126 and a mutation in codon 12 of the H-ras gene. The remaining three cell lines had p53 mutations in intron 5, in codon 193, and a missense mutation in codon 126, respectively. Four of seven cell lines were nontumorigenic; two of these cell lines contained a nonsense p53-126 mutation and mutated ras; one had a missense mutation at codon 126 but no mutated ras; the the fourth had only a p53 mutation at codon 193. Two of the nontumorigenic cell lines were converted to tumorigenicity after treatment with methyl methanesulfonate or N-methyl-N'-nitro-N-nitrosoguanidine with no apparent additional mutations in either gene. Our analysis revealed that there was a high frequency of genetic diversity and mutations in both p53 and H-ras. There was also a lack of a causal relationship in the presence of mutations in p53 and the cells' ability to exhibit a malignant potential in nude mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352120     DOI: 10.1023/a:1007419810705

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  6 in total

1.  Epstein-Barr virus growth-transformed cells are converted to malignancy following transfection of a 1.3-kb CATR1 antisense construct independent of a change in the level of c-myc expression followed by a 8;14 chromosomal translocation.

Authors:  D Li; X L Sun; B Casto; J Fang; K Theil; R Glaser; G Milo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

2.  Storage conditions modulate the metabolomic profile of a black raspberry nectar with minimal impact on bioactivity.

Authors:  Matthew D Teegarden; Thomas J Knobloch; Christopher M Weghorst; Jessica L Cooperstone; Devin G Peterson
Journal:  Food Funct       Date:  2018-09-19       Impact factor: 5.396

3.  Changes in levels of normal ML-1 gene transcripts associated with the conversion of human nontumorigenic to tumorigenic phenotypes.

Authors:  X L Sun; D Li; J Fang; I Noyes; B Casto; K Theil; C Shuler; G E Milo
Journal:  Gene Expr       Date:  1999

4.  Metastatic conversion of chemically transformed human cells.

Authors:  X L Sun; D Li; J Fang; B Casto; I Noyes; G E Milo
Journal:  Gene Expr       Date:  1999

5.  Aliphatic acetogenin constituents of avocado fruits inhibit human oral cancer cell proliferation by targeting the EGFR/RAS/RAF/MEK/ERK1/2 pathway.

Authors:  Steven M D'Ambrosio; Chunhua Han; Li Pan; A Douglas Kinghorn; Haiming Ding
Journal:  Biochem Biophys Res Commun       Date:  2011-05-08       Impact factor: 3.575

6.  Sensitivity to the non-COX inhibiting celecoxib derivative, OSU03012, is p21(WAF1/CIP1) dependent.

Authors:  Haiming Ding; Chunhua Han; Dongmei Guo; Dasheng Wang; Wenrui Duan; Ching-Shih Chen; Steven M D'Ambrosio
Journal:  Int J Cancer       Date:  2008-12-15       Impact factor: 7.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.